Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 7/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.39 |
| ▸ | F10 | P00742 | 1/20 | 0.39 |
| ▸ | SRC | P12931 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14924766 | 0.85 | F2 (0.47) | F2F10SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14924778 | 0.84 | PTGS2 (0.42) | PTGS2SRCSMN1; SMN2MAPTALOX15 | |
| SCHEMBL14924781 | 0.84 | PTGS2 (0.46) | PTGS2PTGDR2SRCSMN1; SMN2MAPT | |
| SCHEMBL12179475 | 0.83 | CYP1A2 (0.43) | PTGS2F2F10MAPTALDH1A1 | |
| SCHEMBL14924764 | 0.80 | F2 (0.34) | F2F10SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL14924747 | 0.77 | KDM4E (0.35) | PTGDR2F2F10SRCSMN1; SMN2 | |
| SCHEMBL14924785 | 0.73 | PTGS2 (0.48) | PTGS2PTGDR2SRCSMN1; SMN2MAPT | |
| SCHEMBL9913271 | 0.73 | F2 (0.39) | F2F10SMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL16919028 | 0.72 | PTGS2 (0.40) | PTGS2SMN1; SMN2MAPTALDH1A1CYP1A2 | |
| SCHEMBL2594260 | 0.71 | CYP1A2 (0.47) | PTGS2SMN1; SMN2MAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8802860-B2 | Method for producing substituted pyridin-2-one | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-08-12 | — | — | US | disclosed |
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130116443-A1 | METHOD FOR PRODUCING SUBSTITUTED PYRIDIN-2-ONE | PNPO, CYP4B1, DPYD | PTGS2 136/4885PTGDR2 287/4885F2 2310/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.